Dissemin is shutting down on January 1st, 2025

Published in

Revista de Chimie, 11(70), p. 3842-3846, 2019

DOI: 10.37358/rc.70.19.11.7656

Revista de Chimie, 11(70), p. 3842-3846, 2019

DOI: 10.37358/rc.19.11.7656

Links

Tools

Export citation

Search in Google Scholar

The Role of BCL2 Protein and Tumour Protein p53 in Septic Cardiomyopathy

This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

A decreased left ventricular ejection fraction (LVEF) was observed in patients suffering from septic shock with normalization of systolic function after 10 days.�Similar courses of reversible myocardial dysfunction due to the systemic inflammatory response syndrome were also encountered in other critical illnesses. Since the pathological and histological mechanisms are not fully understood, the present study tries to understand the septic cardiomyopathy related to the apoptotic pathway. Thestudy included a number of 29�cases of adults that died of septic shock being analysed for BCL2 and p53 expression rates of myocardial tissue. This is the first time the expression of BCL2 protein, p53 tumour protein were evaluated in septic shock and septic cardiomyopathy of humans.�There was a strong link between the increased expression of BCL2 and of p53 protein in cardiac muscle cells in the studied group (p=0.0300).�The study showed a significant correlation between markedly increased values and poor outcome.